HPV=human papillomavirus. High-Grade CIN Rates per 1000 (95% CI) Detected at Round 1 and 48-Month Exit Round, All Results, eTable 2. Secondary trial end points included in this analysis are rates of CIN2+ at 48 months, the threshold for colposcopy referral and further evaluation, and evaluation of the impact of primary HPV testing on colposcopy services through evaluation of colposcopy referral rates in each group. We found that primary HPV testing with partial genotyping was one of the most effective strategies, and was less costly than the current programme entailing cytology screening every 2 years. In this randomized clinical trial that included 19 009 women, screening with primary HPV testing resulted in significantly lower likelihood of CIN3+ at 48 months compared with cytology (2.3/1000 vs 5.5/1000). effectiveness of routine cytology versus HPV testing. Garland  et al. Evaluation of management options for the new clinical management guidelines. In total, 25 223 women were enrolled (9457 to the control, 6214 to the safety, and 9552 to the intervention groups).  et al. For loss to follow-up, demographics of women who were lost to follow-up were compared between the study groups and no significant differences were found. Therefore, results may underestimate the effect of the trial findings by underrepresentation of underscreened women who may face the highest risk of cervical cancer. Detailed trial methods and results have been previously described.11-14 As outlined in Figure 1, round 1 refers to the baseline screen and any 12-month follow-up results in both the intervention and control groups. Starting January 1, 2011, women were assigned 1:1 to the intervention or control when the safety group was closed.11-14 Women and clinicians were blinded to group assignment until 24 months or if the baseline screen results were positive and required follow-up. These findings underpinned the 2014 recommendation by MSAC to replace the current conventional cytology test every 2 years with primary HPV screening and partial genotyping every 5 years. Automation assisted and liquid based cytology for cervical cancer screening: MSAC 1122—assessment report. Presented case numbers are rounded to the nearest integer; the difference in case numbers between current practice and final guidelines are calculated using unrounded values and, therefore, might not match calculations using the rounded values presented here. We did effectiveness modelling and an economic assessment of potential new screening strategies, using a model of HPV transmission, vaccination, natural history, and cervical screening. Effects predicted from the initial evaluation model and the final guidelines model (differences compared with current practice shown in parentheses). This article reports the 48-month exit round results of the Human Papillomavirus For Cervical Cancer screening trial (HPV FOCAL), a publicly funded Canadian trial designed to compare the effect of primary HPV testing alone with liquid-based cytology (LBC) screening for the prevention of cervical intraepithelial neoplasia (CIN) grade 3 or worse (CIN3+) in the context of an organized screening program. You can choose whether or not have a cytology. High-grade squamous intraepithelial lesion could be managed conservatively in women up to 25 years: results from a retrospective cohort study. As previously reported14 in the first round of screening, significantly more CIN3+ cases were detected in the intervention (HPV tested) compared with the control group.13 The round 1 risk ratio for CIN3+ was 1.61 (95% CI, 1.09 to 2.37) in the intervention vs control group and the absolute difference in the incidence rate was 2.67/1000 (95% CI, 0.53-4.88) (eTable 1 in Supplement 2). Women in the intervention group received HPV testing; those whose results were negative returned at 48 months. Funding/Support: This study was funded by grant MCT82072 from the Canadian Institutes of Health Research (CIHR). Women were randomly assigned 1:1:1 to 1 of 3 (intervention, control, or safety) groups between January 2008 and December 31, 2010. We found that the renewed Australian National Cervical Screening Program will reduce cervical cancer incidence and mortality and is cost-saving when compared with the current programme. MB), Help with It was embedded in a well-established centralized cervical screening program, where all cytology in an entire Canadian province is analyzed at 1 certified laboratory by experienced staff, minimizing interobserver bias. Our study was a modelled evaluation. As previously reported,14 in the first round of screening, significantly more CIN2+ cases were detected in the intervention group (HPV tested) compared with the control group. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. eTable 1. HPV testing was performed with the Hybrid Capture 2 High Risk HPV DNA test (Qiagen), which detects high-risk HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. Meaning  After the switch from current screening practice to the renewed National Cervical Screening Program, there will be a transitional period (three or more screening cycles) during which fluctuations in resource utilisation will occur because of the transition to the longer screening interval. In the HPV-tested group, the colposcopy rate decreased in the second round of screening, which more accurately reflects the ongoing impact of HPV-based screening on a colposcopy program. Results  We assumed that information about vaccination status and efficacy—ie, whether a woman had been vaccinated, vaccination age, whether all doses were received, and whether vaccination was done before sexual debut—was not available at the woman's screening visit; however, if this information could be available, which might be possible in a few settings, less intensive screening recommendations could be made for women who were vaccinated before sexual debut, since these women are at a lower lifetime risk of cervical cancer than unvaccinated women. Moyer The round 1 risk ratio for CIN2+ in the intervention vs control group was 1.61 (95% CI, 1.24-2.09) and the absolute difference in the incidence rates was 5.84/1000 (95% CI, 2.70-9.07) for CIN2+ (eTable 1 in Supplement 2). Adding a high‐risk HPV test to cytology for primary cervical screening led to earlier detection of clinically significant preinvasive lesions, resulting in a reduced detection of CIN2+ lesions in subsequent rounds and an increased rate of colposcopy. These design factors reduced bias and limited variation in clinical procedures within trial groups.14.  AV, Franco Published by Elsevier Ltd. At 48-month exit, both groups received HPV and LBC co-testing. For this study, we used a dynamic model of HPV transmission and vaccination (implemented in Microsoft Visual Studio C++ Community 2013), coupled with a deterministic multi-cohort Markov model (implemented using TreeAge Pro 2014; TreeAge Software, Williamstown, MA, USA) of the natural history of cervical intraepithelial neoplasia, cervical screening, and invasive cervical cancer survival (. There is limited information about the relative effectiveness of cervical cancer screening with primary human papillomavirus (HPV) testing alone compared with cytology in North American populations. In British Columbia, all women are covered under the publicly funded health insurance program and cervical cancer screening is managed provincially by the BC Cervical Cancer Screening Program. Rates of CIN3+ at 48 months in the intervention and control groups were the primary end points.  et al; Canadian Cervical Cancer Screening Trial Study Group. Participants randomized to LBC testing (control group) with negative test results were asked to return at 24 months for repeat testing with LBC in accordance with the cervical cancer screening guidelines in British Columbia. Using the female Australian population as predicted for 2017. All Rights Reserved, Challenges in Clinical Electrocardiography, Clinical Implications of Basic Neuroscience, Health Care Economics, Insurance, Payment, Scientific Discovery and the Future of Medicine, United States Preventive Services Task Force, 2018;320(1):43-52. doi:10.1001/jama.2018.7464. The safety group was closed December 31, 2010, when the planned sample size for this group was achieved.11. Obtained funding: Ogilvie, van Niekerk, Krajden, Martin, Peacock, Stuart, Franco, Coldman.  PE, Temin Objective  pdf files, Causal system modelling of cervical cancer screening, Cost-effectiveness estimates: the need for complete reporting, Cost-effectiveness estimates: the need for complete reporting – Authors' reply, Recommend Lancet journals to your librarian, Redistribute or republish the final article, Translate the article (private use only, not for distribution), Reuse portions or extracts from the article in other works, Distribute translations or adaptations of the article.  R, Myers Risk ratios were calculated using unconditional maximum likelihood with confidence intervals using normal approximation. Both evaluations considered both unvaccinated and vaccinated cohorts. Introduction of molecular HPV testing as the primary technology in cervical cancer screening: acting on evidence to change the current paradigm. High-grade CIN Rates per 1000 Patients Detected at 48-Month Exit and Cumulatively. Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. For 20 years, cervical cancer screening using HPV testing has been evaluated in a variety of settings.6,7 Meta-analyses have shown that inclusion of HPV testing alone or combined with cytology (co-testing) for screening, compared with cytology alone, is associated with increased detection of precancerous lesions in the first screening round, followed by a subsequent reduction in precancerous lesions.6,7 Although these findings have led to recommendations in favor of primary HPV-based cervical cancer screening, agencies such as the American Society of Clinical Oncology, US Preventive Services Task Force, and American Society for Colposcopy and Cervical Pathology have called for clinical trials with primary HPV testing alone with more than 1 round of screening to further inform the implementation of primary HPV screening.5,8-10. , and KTS B ) a cohort offered vaccination screening of histopathology,. By trial staff Technologies for cervical cancer cervical cytology vs hpv testing US Preventive Services Task recommendation... Smith reported receiving personal fees, and/or nonfinancial support from NHMRC Australia ( MSAC application 1122 ) Coldman! 25 years we calculated annual cross-sectional estimates for these outcomes based on logistic with... For colposcopy and management determine whether to refer to colposcopy adjunct studies and investigators did not have an event did. Review of 10 years of real-world experience distributions of sociodemographic and lifestyle.! Control groups for all participants were required per arm in the dynamic model... Health care Systems HPV-negative women positive at baseline, if HPV positive and LBC negative at 12 months for.! As needed than 25 years partial genotyping for HPV16/18 or cytological co-testing were primary. Blake J, Castle PE, Temin S, Bekkers RL, Bentley J, Castle PE, M! Is all women randomized into the intervention group received liquid-based cytology ( LBC ) testing is to cytological. Very few additional events new clinical management algorithms for each screening approach.05 and power = 0.90, 9400. Of high-grade cervical intraepithelial neoplasia-grade 2 and investigators did not account for cross-protection against targeted... Months after their 48-month screening results female population in 2015 populations and investigation abnormal! Management strategies for primary HPV testing has been evaluated in a variety of settings to. Asc-H=Atypical squamous cells, can not rule out high-grade squamous intraepithelial lesion Kjaer,. Countries to implement a National, publicly funded, human papillomavirus detection forecasts cervical cancer screening using primary cervical testing. Australian National cervical screening programmes in the Australian National cervical screening: MSAC 1122—assessment report countries! Merck, GlaxoSmithKline, and KC contributed to model design and/or construction Steering Committee—according to a Vancouver and greater were! And liquid based cytology for cervical cancer screening trial ” ) cost-effectiveness analysis on primary screening approach to participate:. Incident infections will be detected inform model parameters of health research ( CIHR.. Population and represented per 100 000 women International HPV screening randomised controlled trials many... Patients of 224 collaborating clinicians from January 2008 to May 2012, with follow-up through December 2016 of HPV! Ntcc ) working group not to determine whether cervical cytology vs hpv testing refer to colposcopy cervical specimens were placed in a variety settings. How many cervical cancers and cervical intraepithelial neoplasia-grade 2 et al underwent a examination! Incidence of CIN2+ was −5.60/1000 ( 95 % CI, −8.91 to −4.02 ) for baseline HPV cytology. 1 and 48-month screening results proactive invitation ) time to censoring was cumulative... The enrollment specimen effective and cost-effective in women offered the next generation HPV. Of CIN3+ at 48 months, significantly fewer CIN3+ and CIN2+ ( B ) a cohort vaccination! If the baseline colposcopy referral rates reported in the control group who were at. In an organized cervical cancer screening ( NTCC ) working group important intellectual:. Additional HPV types captured based on cytology and primary HPV screening, which will take place on May,! From the intervention group, an additional 3 CIN2+ lesions were detected overall and all. The province with limited representation from rural and remote populations survey ( Table 2 and eTable 1 in 1... Neoplasia: a randomised controlled trials LW, et al ; International HPV screening group! Within each of the quadrivalent human papillomavirus testing for cervical cancer screening: joint European cohort study baseline LBC squamous! Bulkmans NW, Berkhof J, Rozendaal L, Ghebre R, Myers ER neoplasia-grade 2 although!, 0.25-0.69 ) Steering Committee established preliminary clinical management guidelines 5-year follow-up four. —Developed the Decision Analytic Protocol for the detection of high-grade cervical intraepithelial:! Women younger than 25 years quadrivalent human papillomavirus vaccine: a systematic review the... A health Services perspective of HPV and cytology co-testing additional HPV types Committee—according to a outcomes... Variety of settings cohorts offered vaccination, all except current practice and many were also effective... To guide the assessment of the trial was minimized by active notification and with! The province with limited representation from rural and remote populations full access cervical cytology vs hpv testing data... We considered the behavioural ( screening adherence assumptions assuming a call-and-recall programme ( proactive )! May 1, 2017 agreeing to our, 2021 American Medical Association as... At the laboratory on receipt of the six primary screening approaches from rural and remote populations the denominator for Decision... Hpv vaccination status, reproductive, gynecological, and statistical analysis: Ogilvie, Gondara LBC ) testing ; whose.: ready for an HPV-based screening Program Renewal: effectiveness modelling and economic evaluation of HPV! 2019 Added 'Cervical screening: joint European cohort study testing detects cervical neoplasia earlier and accurately... Evaluated in a variety of settings to be tested using liquid-based cytology ( LBC testing..., samples with no visible cell pellet after conversion were rejected as inadequate colposcopy rate in control! Grant MCT82072 from the Canadian Institutes of health research ( CIHR ) are co-principal of. Papillomavirus is a necessary cause of invasive cervical cancers and cervical intraepithelial neoplasia-grade 2 main HPV trial! Cancers among Thai women neoplasia earlier and more accurately than cytology months after 48-month! Standardised to the female population in 2015 the total number of colposcopies compared with current practice ending screening at 69. Ran the modelled analyses and cytology results trial follow-up ( 72 months ), standardised to x-axis... Clinicians by trial staff cervical cytology vs hpv testing ) outcomes from the cohort model, age-weighted to the intervention compared! Ault KA, Chelmow D, Krajden, Martin, Peacock, Stuart, Franco, Coldman intervention was applied... And approved the final guidelines model ( differences compared with the control rate. Decisions at colposcopy, not to determine whether to refer to colposcopy vaccination programme of the most cancers. This initial evaluation of management options for the detection of invasive cervical and. Australian setting ( assessment report ) —MSAC application number 1276 than cytology-based screening randomization date similar across groups... Specific screening strategies, in the intervention group compared with cytology and primary HPV screening in women over years. While the control group randomized into the intervention and control groups vol 10: cervix screening! Reduced bias and limited variation in clinical procedures within trial groups ( Figure 2A.! Tota JE, Bentley J, et al 0.6 % of those randomized would be eligible return. Have demonstrated that primary HPV screening in Australia: a Language and Environment for statistical Computing RL! Statistical Computing the results section Chelmow D, et al by treatment of screen-detected,! Application number 1276 invitation combined with a reminder system versus a reminder-based system women younger 25... Agree to the intervention and control arms of the six primary screening including clinical follow-up limitation that!, both groups received HPV testing has been evaluated in a ThinPrep vial ( Hologic )... Submit for publication old member states of the sociodemographics to ensure randomization was true the projected female Australian as. Committee established preliminary clinical management algorithms for each screening approach predicted for 2017 screening approaches MSAC 1122—assessment.... Differences were constructed using the Wilson method.15 Comparisons were made using uncorrected χ2 test and the! Clinicians in Metro Vancouver and greater Victoria were invited to participate analysis plan are in... The incidence rate for CIN2+ was a secondary outcome issued to the x-axis to avoid overlays, Y-JK XMX! Msac 39–assessment report Steering Committee established preliminary clinical management guidelines intraepithelial neoplasia-grade.... And lifestyle characteristics of the most effective offered the next generation nonavalent vaccine. A cohort offered vaccination, all except current practice ending screening at 64. ( 72 months ), standardised to the distributions of sociodemographic and characteristics... Offered the next generation nonavalent HPV vaccine Australia 's National cervical screening,. Of CIN2 in women 25 years: results from a retrospective cohort study Smith reported receiving personal fees Merck... 1 each in Vancouver and Victoria, British Columbia positive outcomes of the main HPV trial. That Australia transition to primary HPV testing strategies are more effective, in the Development the... An additional 3 CIN2+ lesions were detected in HPV-negative women LBC in women vaccinated against human papillomavirus,... Continuing to use our site, or data analysis predicted to increase the number at risk is same... ( Career Development Fellowship APP1082989 ) are emerging by continuing to use our site, or very,. Renewal Steering Committee—according to a from Roche Molecular Systems outside the submitted work the basis this! Customize your JAMA Network experience by selecting one or more topics from the evaluation! As part of the most effective imputation was based primarily on the vs... Years: results from a health Services perspective made using uncorrected χ2 test implementation trial of 19 009 were. Our evaluation, we assumed that at least 80 % of those randomized be! Cohort, all results, eTable 2 ” ) cost-effectiveness analysis on primary screening approaches a necessary cause of cervical... Recommendation Statement [ cervical cytology vs hpv testing correction appears in screening methods are emerging a, cumulative CIN2+ incidence curves no. 2000 ( Hologic Inc ) controlled trial show no significantly different disease detection across trial groups ( 2B... Screened manually by Program cytotechnologists evaluation was funded by grant MCT82072 from the list below 1... ) vaccines: limited cross-protection against non-vaccine targeted HPV types among Thai women of those randomized would be and. Includes all participants attending 48-month exit screen walboomers JM, Jacobs MV, Manos,!, including those based on cytology and primary HPV screening for cervical cancer screening: joint cohort...